Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: A meta-analysis

Researchers performed a meta-analysis of 1,528 patients to evaluate the prevalence of adverse cardiovascular events among adult patients with hematologic malignant neoplasms who received CAR T-cell therapy. They found a low prevalence of ventricular arrhythmia, myocardial infarction, and cardiovascular death over short-term to midterm follow-up. The most commonly reported cardiovascular events were left ventricular dysfunction and supraventricular arrhythmia. Based on these findings, the researchers concluded that cardiovascular surveillance strategies should focus on decreases in ejection fraction and supraventricular arrhythmia.